Erratum: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement (JAMA - Journal of the American Medical Association (2016) 316:19 (1997-2007) DOI: 10.1001/jama.2016.15450);Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement

JAMA - Journal of the American Medical Association

Volumn 316, Issue 19, 2016, Pages 1997-2007

  Bibbins Domingo, Kirsten ^a   Grossman, David C ^b   Curry, Susan J ^c   Davidson, Karina W ^d   Epling, John W ^e   García, Francisco A R ^f   Gillman, Matthew W ^g,h   Kempe, Alex R ⁱ   Krist, Alex H ^j,k   Kurth, Ann E ^l   Landefeld, C Seth ^m   Le Fevre, Michael L ⁿ   Mangione, Carol M ^o   Phillips, William R ^p   Owens, Douglas K ^q   Phipps, Maureen G ^r   Pignone, Michael P ^s  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GROUP HEALTH RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^f Pima County Health Department   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

ⁱ DUKE UNIVERSITY   (United States)

^j Fairfax Family Practice Residency   (United States)

^k VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^l YALE UNIVERSITY   (United States)

^m UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁿ UNIVERSITY OF MISSOURI   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p UNIVERSITY OF WASHINGTON   (United States)

^q STANFORD UNIVERSITY   (United States)

^r BROWN UNIVERSITY   (United States)

^s UNIVERSITY OF TEXAS AT AUSTIN   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ADULTHOOD; AGING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DIABETES MELLITUS; DRUG MEGADOSE; DRUG SAFETY; DYSLIPIDEMIA; HUMAN; HYPERTENSION; LOW DRUG DOSE; MEDICAL RESEARCH; MORTALITY; MUSCLE WEAKNESS; MYALGIA; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SMOKING; SYSTEMATIC REVIEW (TOPIC); UNITED STATES; AGE; AGED; CARDIOVASCULAR DISEASES; COMPLICATION; DIET THERAPY; DYSLIPIDEMIAS; FEMALE; MALE; MASS SCREENING; MIDDLE AGED; RISK ASSESSMENT; STANDARDS; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MASS SCREENING; MIDDLE AGED; PRIMARY PREVENTION; RISK ASSESSMENT;

EID: 85006166338     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2020.0180     Document Type: Erratum

References (45)

1. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129(25)(suppl 2):S49-S73.
2. Rana JS, Tabada GH, Solomon MD, et al. Accuracy of the atherosclerotic cardiovascular risk equation in a large contemporary, multiethnic population. J AmColl Cardiol. 2016;67(18):2118-2130.
3. Cook NR, Ridker PM. Further insight into the cardiovascular risk calculator: The roles of statins, revascularizations, and underascertainment in the Women's Health Study. JAMA Intern Med. 2014;174 (12):1964-1971.
4. DeFilippis AP, Young R, Carrubba CJ, et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. 2015;162(4): 266-275.
5. Mensah GA, Brown DW. An overview of cardiovascular disease burden in the United States. Health Aff (Millwood). 2007;26(1):38-48.
6. Chou R, Dana T, Blazina I, et al. Statin Use for the Prevention of Cardiovascular Disease in Adults: A Systematic Review for the US Preventive Services Task Force: Evidence Synthesis No. 139. Rockville, MD: Agency for Healthcare Research and Quality; 2016. AHRQ publication 14-05206-EF-2.
7. Richardson K, Schoen M, French B, et al. Statins and cognitive function: A systematic review. Ann Intern Med. 2013;159(10):688-697.
8. Yusuf S, Bosch J, Dagenais G, et al; HOPE-3 Investigators. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374(21):2021-2031.
9. Chou R, Dana T, Blazina I, DaegesM, Jeanne T. Statins for prevention of cardiovascular disease in adults: A systematic review and meta-analysis for the US Preventive Services Task Force. JAMA. doi:10.1001/jama.2015.15629
10. Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21): 2195-2207.
11. Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: A systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151(7):483-495.
12. U.S. Preventive Services Task Force. Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151(7):474-482.
13. American Heart Association, American College of Cardiology. Pooled Cohort Equations Cardiovascular Risk Calculator. 2014. http://tools .acc.org/ASCVD-Risk-Estimator/. Accessed September 16, 2016.
14. Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet. 2013;382(9907):1762-1765.
15. Helfand M, Buckley DI, Freeman M, et al. Emerging risk factors for coronary heart disease: A summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151(7):496-507.
16. Dehmer SP, Maciosek MV, Flottemesch TJ. Aspirin Use to Prevent Cardiovascular Disease and Cancer: A Decision Analysis. Rockville, MD: Agency for Healthcare Research and Quality; 2015. AHRQ publication 15-05229-EF-1.
17. Siu AL; U.S. Preventive Services Task Force. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;163(10): 778-786.
18. Siu AL; US Preventive Services Task Force. Behavioral and pharmacotherapy interventions for tobacco smoking cessation in adults, including pregnant women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;163(8):622-634.
19. Chou R, Dana T, Blazina I, DaegesM, Bougatsos C, Jeanne T. Screening for Dyslipidemia in Younger Adults: A Systematic Review to Update the 2008 US Preventive Services Task Force Recommendation: Evidence Synthesis No. 138. Rockville, MD: Agency for Healthcare Research and Quality; 2016. AHRQ publication 14-05206-EF-1.
20. Chou R, Dana T, Blazina I, DaegesM, Bougatsos C, Jeanne TL. Screening for dyslipidemia in younger adults: A systematic review for the US Preventive Services Task Force. Ann Intern Med. 2016;165(8): 560-564.
21. Bibbins-Domingo K, Grossman DC, Curry SJ, et al; US Preventive Services Task Force. Screening for lipid disorders in children and adolescents: US Preventive Services Task Force recommendation statement. JAMA. 2016;316(6):625-633.
22. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: A long term cohort study. BMJ. 2008;337:a2423.
23. Downs JR, Clearfield M,Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279(20): 1615-1622.
24. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25) (suppl 2):S1-S45.
25. Mihaylova B, Emberson J, Blackwell L, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841): 581-590.
26. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841): 565-571.
27. Schatz IJ, Masaki K, Yano K, Chen R, Rodriguez BL, Curb JD. Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: A cohort study. Lancet. 2001;358(9279):351-355.
28. Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, Knook DL, Meinders AE,Westendorp RG. Total cholesterol and risk of mortality in the oldest old. Lancet. 1997;350(9085):1119-1123.
29. Gu Q, Paulose-Ram R, Burt VL, Kit BK. Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012. NCHS Data Brief. 2014;(177):1-8.
30. Johansen ME, Green LA. Statin use in very elderly individuals, 1999-2012. JAMA Intern Med. 2015;175(10):1715-1716.
31. AMDA-The Society for Post-Acute and Long-Term Care Medicine. Ten things physicians and patients should question. http://www.choosingwisely.org/societies/amda-The-society-for-post-acute-and-long-term-care-medicine/. 2015. Accessed September 16, 2016.
32. Bibbins-Domingo K; U.S. Preventive Services Task Force. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016;164(12):836-845.
33. Moyer VA; U.S. Preventive Services Task Force. Screening for coronary heart disease with electrocardiography: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(7):512-518.
34. Siu AL; U S Preventive Services Task Force. Screening for abnormal blood glucose and type 2 diabetes mellitus: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;163(11):861-868.
35. Moyer VA; U.S. Preventive Services Task Force. Behavioral counseling interventions to promote a healthful diet and physical activity for cardiovascular disease prevention in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(5):367-371.
36. Moyer VA; U.S. Preventive Services Task Force. Screening for and management of obesity in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 157(5):373-378.
37. Hoyert DL, Xu J. Deaths: preliminary data for 2011. Natl Vital Stat Rep. 2012;61(6):1-51.
38. Miniño AM. Death in the United States, 2011. NCHS Data Brief. 2013;(115):1-8.
39. Centers for Disease Control and Prevention (CDC). Prevalence of coronary heart disease-United States, 2006-2010. MMWR Morb Mortal Wkly Rep. 2011;60(40):1377-1381.
40. Sever PS, Dahlöf B, Poulter NR, et al; ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet. 2003;361 (9364):1149-1158.
41. Jick SS, Bradbury BD. Statins and newly diagnosed diabetes. Br J Clin Pharmacol. 2004;58 (3):303-309.
42. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in theWomen's Health Initiative. Arch Intern Med. 2012;172(2):144-152.
43. Lopez-Jimenez F, Simha V, Thomas RJ, et al. A summary and critical assessment of the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: filling the gaps. Mayo Clin Proc. 2014;89(9):1257-1278.
44. Anderson TJ, Grégoire J, Hegele RA, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;29(2): 151-167.
45. National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. https://www.nice.org.uk/Guidance/CG181. 2016. Accessed September 16, 2016.